Side effects and watch-outs
- Very short half-life limits practical use
- Insomnia (circadian effects)
- Unknown long-term effects
- Not orally bioavailable according to some research
SARM / Rev-ErbA Agonist
Stenabolic (SR9009)
Rev-ErbA agonist (not technically a SARM but classified with them). Modulates circadian rhythm genes. Increases mitochondrial biogenesis, enhances endurance, reduces fat. No clinical trials. Very short half-life requires dosing every 4 hours for effect. Oral bioavailability debated.
Educational reference only. This page does not diagnose, prescribe, or replace care from a licensed professional. Laws, availability, and clinical appropriateness vary by location.